Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone  (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Lemonnier, François, Safar, Violaine, Beldi-Ferchiou, Asma, Cottereau, Anne-Ségolène, Bachy, Emmanuel, Cartron, Guillaume, Fataccioli, Virginie, Pelletier, Laura, Robe, Cyrielle, Letourneau, Audrey, Missiaglia, Edoardo, Fourati, Slim, Moles-Moreau, Marie-Pierre, Delmer, Alain, Bouabdallah, Reda, Voillat, Laurent, Becker, Stéphanie, Bossard, Céline, Parrens, Marie, Casasnovas, Olivier, Cacheux, Victoria, Régny, Caroline, Camus, Vincent, Delfau-Larue, Marie-Hélène, Meignan, Michel, de Leval, Laurence, Gaulard, Philippe, Haioun, Corinne
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2021
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839364/
https://ncbi.nlm.nih.gov/pubmed/33496747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003081
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars